TY  - GEN
AU  - Wyatt,Ryan M
AU  - Fraser,Ian
AU  - Welty,Natalie
AU  - Lord,Brian
AU  - Wennerholm,Michelle
AU  - Sutton,Steven
AU  - Ameriks,Michael K
AU  - Dugovic,Christine
AU  - Yun,Sujin
AU  - White,Allison
AU  - Nguyen,Leslie
AU  - Koudriakova,Tatiana
AU  - Tian,Gaochao
AU  - Suarez,Javier
AU  - Szewczuk,Lawrence
AU  - Bonnette,William
AU  - Ahn,Kay
AU  - Ghosh,Brahma
AU  - Flores,Christopher M
AU  - Connolly,Peter J
AU  - Zhu,Bin
AU  - Macielag,Mark J
AU  - Brandt,Michael R
AU  - Chevalier,Kristen
AU  - Zhang,Sui-Po
AU  - Lovenberg,Timothy
AU  - Bonaventure,Pascal
TI  - Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor
SN  - 1521-0103
PY  - 2020///0706
KW  - Animals
KW  - Binding, Competitive
KW  - Brain
KW  - drug effects
KW  - Dose-Response Relationship, Drug
KW  - Enzyme Inhibitors
KW  - blood
KW  - Escherichia coli
KW  - enzymology
KW  - HeLa Cells
KW  - Humans
KW  - Kinetics
KW  - Leukocytes, Mononuclear
KW  - Male
KW  - Mice, Inbred C57BL
KW  - Molecular Structure
KW  - Monoacylglycerol Lipases
KW  - antagonists & inhibitors
KW  - Pain
KW  - drug therapy
KW  - Piperazines
KW  - Protein Binding
KW  - Rats, Sprague-Dawley
KW  - Receptor, Cannabinoid, CB1
KW  - agonists
KW  - Receptor, Cannabinoid, CB2
KW  - Sleep, REM
KW  - Substrate Specificity
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1124/jpet.119.262139
ER  -